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Abstract   
Objectives: to examine the cost-effectiveness of continued treatment for patients with moderate-
severe Crohn’s disease in clinical remission, with a combination of anti-TNFα (infliximab) and 
immunosuppressant therapy compared to two different withdrawal strategies (1) withdrawal of the 
anti-TNFα therapy, and (2) withdrawal of the immunosuppressant therapy, respectively.  
  
Material and methods: A decision-tree model (Markov type) was constructed mimicking three 
treatment arms: (1) continued combination therapy with infliximab and antimetabolites, (2) 
withdrawal of infliximab, or (3) withdrawal of the immunosuppressant. Relapses in each arm are 
managed with treatment intensification. State dependent relapse risks, remission probabilities and 
quality of life weights were collected from previous published studies.   
 
Results: Combination therapy was less costly and more efficient than the withdrawal of the 
immunosuppressant, and more costly and more efficient than withdrawal of infliximab. The 
incremental cost-effectiveness ratio for the combination therapy compared with withdrawal of 
infliximab was estimated at SEK 755 449 per additional QALY. This is well above the informal 
willingness-to-pay threshold in Sweden (500 000 SEK/QALY). The estimated cost-effectiveness of 
the combination therapy was found highly sensitive to the unit cost of infliximab; at a 36% lower 
unit cost of infliximab, the combination treatment would become cost-effective. The qualitative 
content of these results were quite robust to changes in the clinical effectiveness and the quality-of-
life figures adopted in the calculations. The qualitative content of these results were quite robust to 
changes in the clinical effectiveness and quality-of-life values.  
Conclusions: Combination therapy using a combination of anti-TNFα (infliximab) and 
immunosuppressant is cost effective in the treatment of Crohn’s disease compared to treatment 
cycles in which the immunosuppressant is withdrawn. Combination treatment is not cost effective 
compared to treatment cycles in which infliximab is withdrawn, at current pharmaceutical prices. 
Key words: infliximab, immunosuppressant, de-escalation, cost-effectiveness 
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INTRODUCTION 
 
The incidence and prevalence of Crohn’s disease (CD) in Western countries range between 5 and 50 
per 100 000 inhabitants (Derek et al., 2013). The healthcare costs associated with CD are 
considerable (Kappelman et al., 2008), and patient’s with CD suffer from significant quality-of-life 
reductions, in particular when the disease is active (Cohen, 2002). Biological treatments, particularly 
anti-TNF-alpha agents, have been demonstrated to improve treatment outcomes. The most effective 
therapy for moderate-severe CD is currently a combination of anti-TNF and purine analogues 
(SONIC trial), which can be considered as the reference standard against which new drugs or drug 
combinations should be compared.  However, the cost of anti-TNF therapy is relatively high 
(Bodger et al., 2009), although the introduction of bio-similars has brought the cost down 
considerably (Schmitz et al., 2017). The British National Institute for Health and Clinical Excellence 
has concluded that maintenance therapy using anti-TNF-alpha agents is not a cost-effective 
approach compared to available treatment alternatives (NICE, 2010). Furthermore, combination 
therapy increases the risk of infectious side-effects with a potential of being life-threatening 
(Toruner, 2008). Thus, to improve safety and contain costs, treatment regimens that cycle the use of 
these agents in order to achieve and maintain disease remission are of great interest. 
 
The cost-effectiveness of various treatments for Crohn’s disease, using anti-TNF-alpha as mono-
therapy or in combinations with an antimetabolite, have been estimated an reviewed in a number of 
studies, for instance Rafia et al. (2016), Erim et al. (2015), Saito et al. (2013), Marchetti et al. (2013), 
Tang et al. (2013) and Dretzke et al. (2011). A recent systematic review of cost-effectiveness studies 
comparing conventional and biological treatments for inflammatory bowel disease (Pillai et al., 2017) 
concluded that treatment with infliximab (and adalimumab) in order to maintain remission is not in 
general cost effective compared to standard treatment in patient with moderate or severe Crohn’s 
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disease. However, the cost-effectiveness of a particular treatment strategy depends critically both on 
the exact content of the strategy and on the comparison alternatives (Tang et al. 2013). For instance, 
maintenance treatment with infliximab as monotherapy was found to be cost effective in treatments 
of patients with moderate to severe Crohn’ disease and when limited to one or two years, see, for 
instance, Bodger et al. (2009). Only a limited number of studies have compared combination therapy 
using infliximab and an antimetabolite with either drug as a monotherapy. No published results 
concerning the cost-effectiveness of maintained combination therapy as compared to treatment 
strategies in which infliximab and the antimetabolite are withdrawn and reintroduced in case of 
relapse. The results reported by Marchetti et al. (2013) and Saito et al. (2013) indicate that 
combination therapy is cost-effective both compared with treatment alternatives that escalate the 
drug treatment provided, and compared with infliximab as monotherapy. Although there is, to the 
best of our knowledge, no published results concerning the cost effectiveness of treatment regimens 
that cycle infliximab and an antimetabolite, the results reported by Saito et al. indicate that sustained 
combination therapy may be cost effective compared to treatments that withdraw the antimetabolite. 
Further, although no cost-effectiveness results concerning infliximab biosimilars could be explicitly 
identified in the literature, the results in recent studies suggest that costs can be reduced and 
treatment effectiveness maintained using infliximab biosimilars in the treatment of Chron’s disease 
(Kim et al., 2017; Schmitz et al., 2017). 
  
No cost-effectiveness results regarding the cost-effectiveness of different withdrawal strategies in 
which treatment is de-escalated in periods of remission were found in the literature. The objective of 
this study was to compare the cost-effectiveness of two de-escalation therapies with continued 
combination therapy using infliximab and an immunosuppressant in patients with Crohn’s disease in 
clinical remission. 
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DATA AND METHODS 
 
We constructed a Markov-type decision-tree model mimicking three maintenance therapies, 
including the two de-escalation strategies mentioned above. Thus, in treatment arm 1 the patients 
continue the combination therapy as previous to randomization. In treatment arm 2, infliximab 
treatment is withdrawn and anti-metabolites treatment is continued, while in arm 3, infliximab 
treatment is continued and anti-metabolites withdrawn. Specific calibrations of the provided 
pharmaceutical treatments in each arm in case of relapse and remission are reported in the detailed 
illustration in the appendix (Figures A1 – A3).  
 
Simulation model 
 
The simulation model was constructed in order estimate the cost effectiveness of the combination 
therapy, using an antimetabolite and infliximab, compared to monotherapy using either the 
antimetabolite or infliximab. The model performs parallel calculations for the three arms using two 
medical states in each arm, in which the patient is either in remission or in relapse, a one-month 
clock frequency, and a time horizon of 2 years. In order to infer the effect on cost effectiveness of a 
longer time horizon the model was extrapolated an additional 5 years. The model is parametrizised 
with separate relapse risks and remission probabilities for the three arms, state-dependent quality-of-
life weights, and state-dependent healthcare costs. The simulation model was populated with 
parameter values collected from published previous studies (specified below). In cases were the 
empirical evidence for a specific parametrization is weak, or non-existent, we have complemented 
our analysis with extensive sensitivity analysis, in order to deduce the significance of the lack of 
knowledge for the results obtained in this study. The model structure corresponds to the clinical 
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situation illustrated in Figures A1 – A3, in the appendix. A more detailed description of the input 
used in the simulation model is provided in the next section.  
 
Health economic evaluation – the cost-effectiveness measure  
This study employs firmly established methods for health economic evaluations (Drummond et al., 
2015). The cost-utility analysis provides a method for relating the attained additional treatment 
effects achieved using a specific intervention (the main alternative) to its additional costs, compared 
with a specific alternative (the comparison alternative). In principle, this is straightforward, however, 
in practice it involves several empirical judgements as to what numerical values to use in the 
calculations. The ratio between cost and effect differences for the compared treatment alternatives is 
the incremental cost-utility ratio (ICUR), defined as: 
 
𝐼𝐶𝑈𝑅 =
𝐶𝑜𝑠𝑡𝑚𝑎𝑖𝑛 𝑎𝑙𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑣𝑒 − 𝐶𝑜𝑠𝑡𝑐𝑜𝑚𝑝𝑎𝑟𝑖𝑠𝑖𝑜𝑛 𝑎𝑙𝑡𝑒𝑟𝑎𝑡𝑖𝑣𝑒
𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑒𝑐𝑡𝑚𝑎𝑖𝑛 𝑎𝑙𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑣𝑒 − 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑒𝑓𝑓𝑒𝑐𝑡𝑐𝑜𝑚𝑝𝑎𝑟𝑖𝑠𝑖𝑜𝑛 𝑎𝑙𝑡𝑒𝑟𝑛𝑎𝑡𝑖𝑣𝑒
. 
 
In general, the cost variable in the expression above should include not only costs associated with the 
two treatment alternatives, but also the cost for all other healthcare utilization. Moreover, the costs 
may also include the indirect effect of the compared treatments on productivity, that is, the effects 
on sickness absenteeism from work and losses that occur due to premature mortality. The dominant 
effect measure in a cost-utility analysis captures the number of life years (or any other unit of time) 
associated with each treatment and the quality of life of each year in a combined measure: The 
quality adjusted life year (QALY). Since neither costs, nor quality of life, can be measured 
unobjectionably, the reporting of results should be complemented with an analysis of how the core 
measure, the ICUR, is affected by alternative quality-of-life- and cost measures (deterministic 
7 
 
sensitivity analysis). Beyond these measurement issues, there is also the question of to what extent 
the parameters that enters into the ICUR measure are afflicted with uncertainty. That is, the effects 
of a treatment and the associated healthcare costs may contain random components. This may be 
dealt with using probabilistic analysis.  
 
Given a set of values reflecting costs and effects of two competing treatment alternatives, the 
incremental cost-utility ratio provides a measure of the incremental cost per QALY associated with 
the main treatment alternative. Whether or not the main treatment alternative should be regarded as 
being “cost effective” as compared with the comparison alternative depends on the societal 
willingness-to-pay for an additional QALY. So, if the incremental cost per QALY gained by using 
the main treatment alternative instead of the comparison alternative is below that threshold value, 
the main alternative is to be considered as cost effective (see the appendix for an elaboration of these 
concepts). The informal willingness-to-pay threshold in Sweden is 500 000 SEK/QALY.        
 
Input data 
This section describes the data collection processes and sources. A summary of the base-case 
numerical specification of the simulation model is reported in Table 1. Specifications as to the 
probabilistic sensitivity analysis are also provided in Table 1. 
 
Clinical effectiveness 
The simulation model incorporates two different parameters reflecting clinical effectiveness, the risk 
of relapse and the likelihood of remission. Information about these clinical effectiveness parameters 
was collected for each treatment arm separately. The proportion of the patient population that 
relapse within 24 months (risk of relapse) were used to calculate the monthly relapse rate in each 
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treatment arm (Adegbola et al., 2018; Boyapati et al., 2018; Fria Gomes et al., 2018; Torres et al., 
2015; Louis et al., 2012). Relapse rates and remission likelihoods in arm 1 and 3 were assumed to be 
constant over time, while the relapse rater in arm 2 (infliximab withdrawal) was calculated separately 
for three consecutive time intervals, 2 – 8 months, 9 – 14 months, and 15 – 24 month, using the 
information that about 50 % of the patients relapse within 24 months (for details, see Table 1). The 
likelihood of remission after a relapse was assumed to be 65 % in arm 1 (Baert et al., 2013; Chaparo 
et al., 2011; Lin et al., 2013; Steenholdt et al., 2015), and 70 % in arm 3 (after infliximab escalation 
and reintroduction of the antimetabolite) (Baert et al., 2013; Chaparo et al., 2011; Lin et al., 2013; 
Ungar et al., 2017). The corresponding likelihoods in arm 2 were assumed to be 80 % and 90 %, 
respectively, for the reinstatement of infliximab at 5 mg and 10 mg (Kennedy et al., 2016; Torres et 
al., 2015).  
 
The validity of the core of the simulation model – how well it projects patients in the different health 
states – based on the clinical effectiveness parameters used is illustrated by the number of patients, in 
each arm, who are modelled as being in remission or classified as treatment failure at each point in 
time. These simulations are illustrated in Figures 1 and 2. 
 
    --- Figure 1 about here --- 
   --- Figure 2 about here --- 
 
Notice, the higher number of treatment failures in the treatment arm in which the antimetabolite is 
withdrawn is explained by the relatively high likelihood of regaining remission in the treatment arm 
in which infliximab is withdrawn (see Table 1).  
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Quality of life 
Quality-of-life weights were collected from Saito et al. (2013), Table 1, Quality of life utilities; utility 
weights for the health states Remission (remission in our model), Mild disease (relapse in our model), 
and Non-responding active disease (failure in our model).  
 
Pharmaceutical treatment costs 
Pharmaceutical treatment costs were calculated using Swedish unit costs (The Dental and 
Pharmaceutical Benefits Agency) for 2017. The monthly pharmaceutical treatment costs were 
estimated at SEK 4 924 (infliximab 5 mg), SEK 9 849 (infliximab 10 mg), and SEK 210 
(antimetabolites). Pharmaceutical treatment costs in case of treatment failure are assumed to 
correspond to combination treatment with infliximab 10 mg and antimetabolites. 
 
Medical treatment costs 
Medical treatment costs comprise costs associated with outpatient visits and hospitalizations, with 
and without surgery. Every relapse was assumed to result in either one outpatient visit to hospital 
clinic, in 90 % – 95 % of the cases, or in hospitalization, in 5 % – 10 % of the cases. Between 0 % 
and 3 % of the hospitalized were assumed to be subject to surgery. The corresponding figures for 
those characterized as treatment failures, were 70 % – 80 % are hospitalized and between 3 % and 10 
% subject to surgery. No distinctions between treatment arms were considered. 
 
Unit costs were collected from the diagnosis-related groups (DRG) statistics issued by the Swedish 
National Board of Health and Welfare. The DRG statistics report DRG weights for every medical 
procedure, and a cost per a one-unit weight (SEK 54 254). Thus, the unit cost for surgery used in our 
calculations was calculated as the weighted sum of DRG weights for bowel surgery without 
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complications, with complications and with severe complications. The unit cost for surgery was 
estimated at SEK 158 313. The unit costs for inpatient- and outpatient care visits were estimated as 
the costs corresponding to the DRG weights for inpatient- and outpatient care due to inflammatory 
bowel disease, SEK 42 915 and SEK 4 774, respectively.  
 
Discounting 
Following the guidelines issued by National Institute for Health and Care Excellence (NICE), costs 
and effects were discounted monthly at a 3.5 % annual discount rate. 
 
Sensitivity analysis 
We performed both one-way deterministic sensitivity analysis and probabilistic sensitivity analysis, 
pertaining to the core parameters of the simulation model.  
 
Deterministic sensitivity analysis  
We performed one-way deterministic sensitivity analysis for ∓ 10 % variation of (1) the relapse rate 
for patients treated with a combination therapy, in either treatment arm, (2) relapse rates for 
monotherapies with infliximab or an immunosuppressant, (3) the remission rates for the infliximab 
10 mg monotherapy and the combination therapy alternatives, and (4) utility weights for the states 
remission, relapse, and failure, (5) healthcare costs associated with relapse and treatment failure, 
respectively, and (6) pharmaceutical (infliximab) costs. Additional sensitivity analyses were performed 
for (1) the impact of infliximab price reductions on the cost effectiveness of combination therapy 
were performed, and (2) the relapse rate associated with infliximab withdrawal.      
 
Probabilistic sensitivity analysis 
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Data on treatment effectiveness, and the associated healthcare utilization, comprises uncertainty due 
to the fact that a given treatment does not guarantee a specific outcome. Deterministic sensitivity 
analysis is useful for examining the range of a specific parameter for which the incremental cost-
utility ratio falls below a specified threshold value, but it produces no information as to the probability 
of achieving a cost-utility ratio which falls below that threshold value. The distribution of the ICUR 
can be calculated employing Monte Carlo simulations or bootstrapping (Drummond et al., 2015). 
The Monte Carlo approach involves specifying statistical distributions for the parameters that are 
examined, while the bootstrapping method relies on random sampling with replacement from 
primary data. Thus, while Monte Carlo simulation imposes additional assumptions on the data 
generation process the bootstrapping method does not. Simulations with either method will produce 
an estimate of the distribution of the ICUR. In this study, we used Monte Carlo simulations, since 
primary data for the clinical trial is not yet available. 
 
Monte Carlo simulations involving all relapse rates, remission likelihoods, and healthcare costs were 
performed. Adopting the method for performing probabilistic sensitivity analysis outlined by Briggs 
et al. (2006) the following assumptions were made: (1) all probabilities were assumed to be Beta-
distributed, and (2) healthcare costs were assumed to be lognormally distributed (for details, see 
Table 1). 
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Table 1. Numerical base-case specification of the simulation model. Risks and probabilities are reported as per-month values. Deterministic model and 
specification of parameters used in the probabilistic sensitivity analysis. 
Quality of life weights+ Pharmaceutical and medical treatment unit costs++ Share of patients being hospitalized and 
being subject to surgery 
Remission 0.89 IFX: dose 5mg / 10 mg / 2 
months / kg (patient 
weighing 70 kg) 
SEK 4 924 / SEK 9 849+++ Hospitalization when 
relapsing 
8 % 
Relapse  0.77 (mild 
disease in Saito) 
AZA: dose 5mg/day/kg SEK 210+++ Hospitalization when 
treatment failure 
25 % 
Treatment failure 0.40 (non-
responding 
active disease) 
Surgery SEK 158 313 Surgery when relapsing 2 % 
  Inpatient care (without 
surgery) 
SEK 42 915 Surgery when treatment 
failure 
4 % 
  Outpatient care SEK 4 774   
Rate of relapse / remission 
First arm (IM + IFX) Second arm (discontinuing infliximab) Third arm (discontinuing anti-
metabolites) 
Risk of relapse for 
combination 
therapy* 
0.0044 Risk of relapse 2-8 months** 0.0353 Risk of relapse (IFX 5 
mg)*** 
0.0093 
Probability of 
remission for 
combination 
therapy (IM+IFX 
10mg) 
0.65 Risk of relapse 9-15 months 0.0299 Probability of remission 
(IFX 10 mg)**** 
0.60 
  Risk of relapse 15-24 months 0.0221 Probability of remission 
for combination therapy 
(IM+IFX 10mg)**** 
0.25 
  Probability of remission 
(IM+IFX 5mg)  
0.8 Risk of relapse for 
combination therapy 
(IM+IFX 5mg)* 
0.0044 
  Probability of remission 
(IM+IFX 10mg) 
0.9 Probability of remission 
for combination therapy 
0.65 
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(IM+IFX 5mg) 
Table 1. Continued. Probabilistic sensitivity analysis 
  Mean Standard deviation Remark 
Rate of relapse Beta distribution Base-case value above 14 % of base-case value (Saito et al., 2013)  
Rate of regaining remission Beta distribution Base-case value above 14 % of base-case value (Saito et al., 2013)  
Quality of life weights Beta distribution Base-case value above 10 % of base-case value (Saito et al., 2013)  
Pharmaceutical costs Log-normal distribution Base-case value above 40 % of base-case value (Saito et al., 2013)  
Healthcare cost in case of relapse Log-normal distribution Base-case value above 40 % of base-case value No cost range 
reported in Saito 
et al., 2013 
Healthcare cost in case of failure Log-normal distribution Base-case value above 40 % of base-case value (Saito et al., 2013)  
+ Source: Saito et al. 2013; 
++ Source for Pharmaceutical unit costs: The Dental and Pharmaceutical Benefits Agency. Source for dosage: FASS. Source for surgery cost and cost per 
hospitalization and outpatient visit: published DRG weights (Diagnose Related Groups) and cost per weight unit, published by the Swedish National Board of 
Health and welfare. 
+++ Monthly treatment cost in case of treatment failure is 9 849 + 210. 
* 10 % of the patient population is relapsing within 24 months. Assuming a constant rate, r, of relapsing we have: (1 − 𝑟)24 = 0.9; 
** calculated assuming that 50% of the patients relapse over the 24-months trial, and that 50% of the patients relapsing do so between months 2 and 8, 25% of 
the patients relapse between month 9 and 14, and 25 % of the patients relapse between months 9 and 24. 
*** 20 % of the patient population is relapsing within 24 months. Assuming a constant rate, r, of relapsing we have: (1 − 𝑟)24 = 0.8; 
**** 70 % of patient gain remission after infliximab escalation to 10 mg and reintroduction of AZA. Assuming that 60 % regain remission after the escalation 
of infliximab. Thus, the additional remission rate, 𝑟, is given by 0.6 + (1 − 0.6) ∙ 𝑟 = 0.7 
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RESULTS 
 
The results are presented in Table 2. For the base-case input data (Table 1), the following outcomes 
are reported for the 24-month period (per 1000 patients): (1) total incremental intervention cost (the 
additional pharmaceutical cost imposed by combination treatment compared to discontinuing 
infliximab and to discontinuing anti-metabolites, respectively), (2) total healthcare costs averted 
(additional healthcare costs accruing from treatment failure), (3) total QALYs gained (the number of 
life years gained adjusted for the gain in quality of life obtained by combination treatment), and (4) 
the incremental cost per QALY gained.  
 
Base-case 
Combination treatment is more costly and more efficient than treatment involving discontinuing 
infliximab. The incremental cost-effectiveness ratio was estimated at 755 449 SEK per additional 
quality-adjusted life year and, hence, combination treatment is not cost-effective compared with the 
withdrawal of infliximab, using a 500 000 SEK/QALY threshold. Comparing combination treatment 
with treatment involving discontinuing antimetabolites shows that combination treatment is both 
less costly and more efficient, resulting in savings per additional quality-adjusted life year. Thus, for a 
willingness-to-pay threshold for an additional QALY, maintained combination treatment is cost-
effective compare with withdrawing the metabolite and withdrawing infliximab, respectively.  
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Table 2. Treatment cost, treatment failure cost, quality-adjusted life years, incremental cost-effectiveness. Base 
case, per 1000 patients 
Treatment arm 1 - combination treatment  Treatment arm 1 vs treatment arm 2 
Treatment cost      121 041 196      
 Incremental 
cost              86 952 369     
Failure cost          3 870 450      
 Incremental 
utility                           115     
QALYs                  1 688      ICUR                  755 449     
     
Treatment arm 2 - discontinuing infliximab  Treatment arm 1 vs treatment arm 3 
Treatment cost        33 459 553      
 Incremental 
cost  -  3 511 625     
Failure cost          4 499 724      
 Incremental 
utility                             44     
QALYs                  1 573      ICUR - 79 933     
     
Treatment arm 3 - discontinuing AZA    
Treatment cost      121 832 925        
Failure cost          6 590 347        
QALYs                  1 644        
 
Sensitivity analyses 
The incremental cost-effectiveness ratio was relatively insensitive to  ∓ 10 % variations (from base-
case values) in the input variables except the unit cost of infliximab, as can be seen from the 
reporting of the deterministic sensitivity analysis, Table 3. Thus, the qualitative content of the base-
case results – that maintained combination treatment is cost effective compared to the withdrawal of 
the antimetabolite and not cost effective compared to the withdrawal of infliximab – were unaltered 
by the univariate changes considered. The parameterization of the remission likelihoods in arm 3 
(discontinuing the antimetabolite) was particularly inflicted with uncertainty and, hence, we 
performed additional sensitivity analyses in this case. Varying the remission likelihoods associated 
with infliximab escalation and reintroduction of the antimetabolite, respectively, by ∓ 50 % from 
base-case values (60 % and 25 %) resulted in lower costs and additional QALYs for the combination 
treatment alternative in both cases, and, hence, the qualitative result that maintaining combination 
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therapy both saves resources and produces more QALYs is robust. Moreover, since the price of 
infliximab can be expected to decrease in the future, as the utilization of biosimilars increase, we 
calculated incremental cost-effectiveness ratios for a range of infliximab prices (per 100 mg). The 
result is illustrated in Figure 7. The infliximab price-threshold for when the combination therapy will 
be assessed as being cost effective at SEK 1 865/100 mg.   
 
In addition to the sensitivity analyses reported in Table 3, we explored the scenario in which patients 
who have either a low or a high risk (in relation to the base-case 20 %) of relapse when infliximab is 
withdrawn can be identified. We estimated the threshold share of patients who relapse within 24 
month when infliximab is withdrawn which would make this treatment alternative cost effective 
compared to continued combination therapy: if 12,8 % (or less) of the patients relapse (within 24 
month), infliximab withdrawal produces better quality-of-life outcomes at a lower cost than 
continued combination therapy. If 60 % (or more) of the patients relapse when infliximab is 
withdrawn, the combination therapy becomes cost effective. Further, we extrapolated the cost-
effectiveness results to a 7-year time perspective, assuming that 80 % of the patients relapse over this 
period and that all other relapse risks and remission likelihoods remain the same. These calculations 
show that the incremental cost per QALY increases with the time horizon for the comparison 
between continued combination therapy and infliximab withdrawal. Combination therapy stays more 
efficient and less costly than antimetabolite withdrawal.   
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Table 3. Results of the deterministic sensitivity analysis. Incremental costs, effects, and cost-effectiveness ratios are reported for the arm 1 vs arm 2 and for the arm 1 
vs arm 3 comparisons.  
 Relapse rates Healthcare cost 
 
Changes in treatment arm 1 (relapse for 
combination therapy, AZA + IFX 5 mg and 
AZA + IFX 10 mg) 
Changes in medical care cost 
associated with a relapse 
Changes in medical care cost 
associated with treatment failure 
 + 10 % - 10% + 10 % - 10% + 10 % - 10% 
Treatment arm 1 vs 
treatment arm 2   
   
 Incremental cost              87 110 026                 86 793 490                 86 920 304                 86 984 434                 86 932 238                 86 972 500     
 Incremental utility                           112                              118                              115     
                         
115     
                         
115     
                         
115     
ICUR                  776 042                      735 798                      755 170                     755 727                     755 274                     755 623     
Treatment arm 1 vs 
treatment arm 3   
   
 Incremental cost  -            3 351 189     -            3 673 287     -            3 542 927     -            3 480 324     -            3 553 534     -            3 469 717     
 Incremental utility                             41                                47                                44     
                           
44     
                           
44     
                           
44     
ICUR -                  81 551     -                  78 526     -                  80 646     -                 79 221     -                 80 887     -                 78 979     
 
Changes in treatment arm 2 (relapse for AZA-
monotherapy) 
 
  
Treatment arm 1 vs 
treatment arm 2   
  
  
Incremental cost              84 376 521                 89 643 634         
 Incremental utility                           130                              100         
ICUR                  647 715                      896 595         
 
Changes in treatment arm 3 (relapse for IFX 
monotherapy) 
  
  
Treatment arm 1 vs 
treatment arm 3   
  
  
 Incremental cost  -            4 401 265     -            2 604 171         
 Incremental utility                             51                                37         
ICUR -                  86 307     -                  70 714         
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Table 2. Continued. 
 Utility weights, relapse Utility weights, remission Utility weights, treatment failure 
 + 10 % - 10 % + 10 % - 10 % + 10 % - 10 % 
Treatment arm 1 vs 
treatment arm 2    
   
 Incremental cost              86 952 369                 86 952 369                 86 952 369                 86 952 369                 86 952 369                 86 952 369     
 Incremental utility                           112                              118                              129     
                         
101     
                         
115     
                         
115     
ICUR                  773 106                      738 580                      672 037                     862 499                     756 415                     754 485     
       
Treatment arm 1 vs 
treatment arm 3    
   
 Incremental cost  -            3 511 625     -            3 511 625     -            3 511 625     -            3 511 625     -            3 511 625     -            3 511 625     
 Incremental utility                             43                                45                                48     
                           
40     
                           
45     
                           
43     
ICUR -                  81 897     -                  78 062     -                  72 735     -                 88 713     -                 77 983     -                 81 983     
 
Remission rate, IFX 10 mg  
(arm 3) 
Remission rate, AZA + IFX 5 mg (arm 
2) 
Remission rate, AZA + IFX 10 mg 
(arm 1) 
Treatment arm 1 vs 
treatment arm 2 + 10 % - 10 % + 10 % - 10 % + 10 % 10% 
 Incremental cost  - -             87 333 528                 86 571 210                 86 913 768                 86 990 483     
 Incremental utility  - -                          114     
                         
117     
                         
115     
                         
115     
ICUR - -                  769 369                     741 907                     752 534                     758 360     
       
Treatment arm 1 vs 
treatment arm 3   
    
 Incremental cost  -            3 301 276     -            3 720 166     - - -            3 929 748     -            3 095 064     
 Incremental utility                             38                                50     - - 
                           
46     
                           
41     
ICUR -                  86 840     -                  74 683     - - -                 84 672     -                 74 650     
       
 Pharmaceutical cost (infliximab)     
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 + 10 % - 10 %     
Treatment arm 1 vs 
treatment arm 2   
    
 Incremental cost              95 669 857                 78 234 881        
 Incremental utility                           115                              115        
ICUR                  831 187                      679 710        
Treatment arm 1 vs 
treatment arm 3   
    
 Incremental cost  -            4 271 571     -            2 751 680        
 Incremental utility                             44                                44        
ICUR -                  97 231     -                  62 635        
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Probabilistic sensitivity analysis were performed for 10 000 random draws of the simulated 
parameters. The results of probabilistic sensitivity analysis are presented in Figures 3 – 6. Figures 3 
and 5 plots all pairs of incremental cost and quality-adjusted life years produced by the Monto-Carlo 
simulation in the cost-effectiveness plane, while Figures 4 and 6 plots the share of incremental cost-
effectiveness ratios falling below certain willingness-to-pay thresholds. It is clear from Figure 3 that 
most of the random cost-effectiveness pairs are located in the first quadrant in the cost-effectiveness 
plane indicating that the combination therapy is both more costly and more effective than the 
alternative of infliximab withdrawal. Whether or not any given point is characterized as being cost 
effective depend on the willingness to pay (WTP) for an additional quality adjusted life year (QALY). 
The straight line from the origin marks the SEK 500 000 willingness to pay for an additional QALY 
and, hence, all points situated below that line encompass cost-effective combinations of incremental 
costs and effects. Clearly, as the majority of all random pairs are situated above this line, the 
combination therapy has a low likelihood of being cost effective. Similarly, for the comparison 
between combination therapy and withdrawal of anti-metabolites roughly half of the random cost-
effectiveness pairs are located in the first quadrant, with the majority being below the willingness-to-
pay threshold. The random pairs located in the fourth quadrant illustrate situations in which the 
combination therapy is less costly but more effective. Figures 5 and 6 show that the likelihoods of the 
combination therapy being cost effective when compared to the withdrawal of infliximab and the 
withdrawal of anti-metabolites, respectively, are about 25 % and 65 %.   
 
FIGURES 3 – 6 ABOUT HERE 
 
 
CONCLUSION 
 
In this study, we estimated the cost-effectiveness of the biological therapy cycles, which constitute 
established clinical practice in the management of Crohn’s disease. Thus, combination therapy with 
21 
 
infliximab and anti-metabolites were compared with the two treatment alternatives of withdrawing 
infliximab and anti-metabolites, respectively. For the base-case setting of the parameter values 
entering into our calculations the costs per additional QALY for the combination therapy, as 
compared to the withdrawal of infliximab and the withdrawal of the antimetabolite, were estimated 
at SEK 755 449 and – SEK 79 933 (lower cost and higher effect), respectively. Thus, the 
combination therapy is not cost-effective as compared to the withdrawal treatment strategy, for the 
threshold of the willingness-to-pay for an additional QALY that is usually applied in Sweden.  
 
DISCUSSION 
 
We analyzed the cost-effectiveness of a combination treatment for patients with Crohn’s disease as 
compared to two withdrawal/reintroduction strategies, using a two-year time perspective. The 
medical scientific literature does not provide information on the clinical effectiveness parameters – 
relapse and remission rates – corresponding exactly to the clinical situations that were compared in 
this study. Instead, the cost-effectiveness calculations were performed applying parameter values 
collected from clinical studies corresponding closely to the treatments compared here. This approach 
was complemented with extensive analyses of the sensitivity of the cost-effectiveness measure to the 
parameter values.       
 
In the near future primary treatment effectiveness data will be available. The treatment alternatives 
compared in this study correspond to the three treatment alternatives studied in the on-going 
SPARE trial, which is an open label, multicenter, trial with three parallel arms, in which patients who 
are in sustained clinical remission without steroids for at least six months, and have been treated by a 
combination of antimetabolites and infliximab for at least one year prior to enrollment, are 
randomized to one of three maintenance therapies. The SPARE trial study design corresponds to the 
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clinical situation illustrated in Figures A1 – A3 in the appendix. In treatment arm 1 the patients 
continue the combination therapy as previous to randomization. In treatment arm 2, infliximab 
treatment is withdrawn and anti-metabolites treatment is continued, while in arm 3, infliximab 
treatment is continued and anti-metabolites withdrawn. In all treatment arms the pharmaceutical 
treatment is modified in response to relapse and attained remission. To the best of our knowledge, 
this is the first study which attempt to estimate the cost-effectiveness of maintained combination 
treatment, as compared to drug withdrawal and reintroduction/reescalation in case of relapse, in 
patients with Crohn’s disease.   
 
Saito et al. (2013) calculated the cost-effectiveness of induction and maintenance treatment with 
infliximab in combination with azathioprine as compared to induction and maintenance treatment 
with infliximab as mono-therapy at about SEK 45 000. Our setting is not identical to the clinical 
setting analyzed by Saito et al., but the similarities between ours and their setting renders the 
observation that their estimated cost-effectiveness is in the same range as our figure significance. 
  
The sensitivity analyses performed showed that the estimated cost-effectiveness of the combination 
therapy, as compared to the two withdrawal treatment strategies, is relatively insensitive to changes in 
the parameters values used in the calculations. The intuitive explanation for this finding is that, 
except for risks of relapse, all parameters appear in the cost and effect calculations in all treatment 
arms. For instance, since infliximab is used by some share of patients in all arms, the effect of an 
infliximab price change for the treatment cost in arm 1 will be partly offset by a corresponding price 
change in the comparator arm.  
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APPENDIX 
 
Figure A1. Treatment arm 1 (Continuing the combination therapy) 
Assumptions about relapse and remission risks and probabilities: relapse risks equal for every point in time for the 24 months, based on an 
assumption of a linear decline in the number of patients who has not relapsed.  The probability of remission from a relapse depends on the 
treatment intensification, in this case from AZA+IFX 5mg to AZA+IFX 10 mg. Quality of life weights are assumed independent on 
treatment paths and depend on the state only. Three different quality-of-life weights are incorporated: for the no relapse/remission state, 
the relapse state, and the treatment failure state. Treatment after the second relapse repeats the cycle. 
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Figure A2. Treatment arms 2 (discontinuing infliximab) 
Assumptions about relapse and remission risks and probabilities: relapse risks are different for 2 – 8 months, 9 – 14 months, and 15 – 25 
months after randomization. Risks are calculated for these time intervals in accordance with previously discussed diminishing risk over time. 
After a relapse, once the patient enters the lower part of the three structure, the risk of relapse is the same as before the first relapse, i.e., the 
risk of relapse depends on time only. The justification for this is that after a relapse and subsequent remission the patient returns to the 
baseline treatment of the treatment arm. The probability of remission from a relapse depends on the treatment intensification. So, for 
example, the probability of remission differs from AZA+5 mg IFX and AZA + 10 mg IFX. Quality of life weights are assumed 
independent on treatment paths and depend on the state only. Three different quality-of-life weights are incorporated: for the no 
relapse/remission state, the relapse state, and the treatment failure state. 
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TREATMENT ARM 3 (DISCONTINUING AZA) 
Assumptions about relapse and remission risks and probabilities: relapse risks equal for every point in time for the 24 months, based on an 
assumption of a linear decline in the number of patients who has not relapsed.  The probability of remission from a relapse depends on the 
treatment intensification. Thus, the probability of remission differs between 10 mg IFX and 10 mg IFX + AZA. Quality of life weights are 
assumed independent on treatment paths and depend on the state only. Three different quality-of-life weights are incorporated: for the no 
relapse/remission state, the relapse state, and the treatment failure state. Treatment after the second relapse repeats the cycle. 
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